Robotic Assisted Kidney Cancer Surgery Proves to be Beneficial to Patients
CHICAGO (April 28, 2009) – Fox Chase Cancer Center researchers find that outcomes of robotic assisted kidney cancer surgery, when performed by experienced surgeons at high volume centers, prove more beneficial to patients when compared to open surgery. The study, authored by Fox Chase robotic surgeon Rosalia Viterbo, MD, was presented today at the American Urological Association’s Annual Meeting,
The standard treatment for kidney cancer is to surgically remove the entire or a portion of the kidney. This is known as nephron-sparing surgery, or partial nephrectomy, and is commonly performed using traditional open surgery. Recently, there has been interest in applying a laparoscopic approach for this procedure, however it has proven to be technically challenging to many surgeons.
Experienced laparoscopic surgeons at high volume centers, such as Fox Chase, are now using the da Vinci® robot assisted surgical system for patients with kidney cancer, or renal cell carcinoma. The advanced technology has enabled faster and greater technical proficiency allowing for completion of complex surgical procedures, facilitating a minimally invasive approach for partial nephrectomy.
“Our patients have experienced many benefits from the robot assisted approach, including shorter hospital stays (average 3 days), preserved kidney function (reduced need for dialysis), smaller scars with optimal cosmetic results, lower blood loss and easier and earlier return to normal activity,” says Viterbo.
As a result of the fast recovery, patients do not delay the next step in their treatment plan, chemotherapy or radiation therapy, stopping the disease from progressing as fast. Similarly, patients with disease on both kidneys benefit because there is less waiting time between surgeries and there is no delay on further treatment. Again, this provides less opportunity for the cancer to grow and spread.
William Krassan came to Fox Chase after learning he had renal cell carcinoma in the right kidney and cystic renal cell carcinoma in the left. Using the da Vinci robot, Viterbo performed a partial nephrectomy on each kidney, just 8 weeks apart. This laparoscopic approach allowed the surgeon to reach the kidney through 4 tiny holes in the patient’s abdomen. Open surgery would have required one large incision in his back and a longer time until the next surgery could have occurred.
"The procedure and recovery were fairly painless and easy,” says Krassan. Dr. Viterbo did a wonderful job in an expeditious way. She was able to save 90 percent of my right kidney and two-thirds of my left kidney."
Viterbo added, “Results of the study show robot assisted partial nephrectomy to be a safe and technically feasible minimally invasive approach to kidney sparing surgery.”
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.